Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy

Banerjee, Indranil; Kyle, Dennis E.; Mukherjee, Dilip; Dey, Goutam; Chattopadhyay, Sankha; Mukherjee, M.; Mandal, Mahitosh; Bandyopadhyay, Amitabha; Gupta, Amit; Ganguly, Shantanu; Misra, Mridula

doi:10.1016/j.actbio.2016.04.026

Cited by 75 publications

(79 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study demonstrated excellent tumor growth inhibition and enhanced survival by an antiangiogenic (CD31 inhibition) and antitumor effect of PTX in orthotopic glioma-bearing rats. Additionally, the authors studied tumor vasculature and tumor targeting efficiency of NPs by conjugating 99 mTc [96].In another recent study, the authors demonstrated significant suppression of angiogenesis by targeting oxaliplatin loaded PEGylated cationic liposomes in a dorsal air sac mouse model [97]. Earlier this century, Sengupta et al [98] and Ebos et al [20] developed polymer lipid hybrid nanocarriers for delivery of combretastatin (an anti-angiogenesis drug) along with doxorubicin as a chemotherapeutic.…”

Section: Lipid-based Nanoparticles For Antiangiogenic Therapymentioning

confidence: 99%

Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer

Mukherjee¹,

Madamsetty

Paul

et al. 2020

IJMS

View full text Add to dashboard Cite

Angiogenesis is a process of generation of de-novo blood vessels from already existing vasculature. It has a crucial role in different physiological process including wound healing, embryonic development, and tumor growth. The methods by which therapeutic drugs inhibit tumor angiogenesis are termed as anti-angiogenesis cancer therapy. Developments of angiogenic inhibiting drugs have various limitations causing a barrier for successful treatment of cancer, where angiogenesis plays an important role. In this context, investigators developed novel strategies using nanotechnological approaches that have demonstrated inherent antiangiogenic properties or used for the delivery of antiangiogenic agents in a targeted manner. In this present article, we decisively highlight the recent developments of various nanoparticles (NPs) including liposomes, lipid NPs, protein NPs, polymer NPs, inorganic NPs, viral and bio-inspired NPs for potential application in antiangiogenic cancer therapy. Additionally, the clinical perspectives, challenges of nanomedicine, and future perspectives are briefly analyzed.

show abstract

Section: Lipid-based Nanoparticles For Antiangiogenic Therapymentioning

confidence: 99%

Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer

Mukherjee¹,

Madamsetty

Paul

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…These barriers are the major challenges when treating brain tumors. Bevacizumab (BVZ) [4,20], Temozolomide, (TMZ) [19], Doxorubicin (DOX) [16] Paclitaxel [8], and Sorafenib (SFN) [15] are some of the anti-angiogenic drugs that have been proven to be effective when transported across the BBB using nano-carriers (see Table 1).…”

Section: Anti-angiogenic Nanomedicine For Brain Diseasesmentioning

confidence: 99%

“…Recently, NMs have been investigated for their efficacy in treating brain angiogenesis conditions. These have included nano-capsules, such as solid lipid nanoparticles (SLNs) [4][5][6][7][8], liposomes [9][10][11][12][13][14][15][16], exosomes [17], and others [18], as well as nano-scaffolds made of chitosan [19], polymers [20,21], inorganic nanoparticles (NPs) [22][23][24], etc. (see Table 1).…”

mentioning

confidence: 99%

Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases

Parimalam

Bădilescu

Sonenberg

et al. 2019

IJMS

View full text Add to dashboard Cite

There is a huge demand for pro-/anti-angiogenic nanomedicines to treat conditions such as ischemic strokes, brain tumors, and neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Nanomedicines are therapeutic particles in the size range of 10–1000 nm, where the drug is encapsulated into nano-capsules or adsorbed onto nano-scaffolds. They have good blood–brain barrier permeability, stability and shelf life, and able to rapidly target different sites in the brain. However, the relationship between the nanomedicines’ physical and chemical properties and its ability to travel across the brain remains incompletely understood. The main challenge is the lack of a reliable drug testing model for brain angiogenesis. Recently, microfluidic platforms (known as “lab-on-a-chip” or LOCs) have been developed to mimic the brain micro-vasculature related events, such as vasculogenesis, angiogenesis, inflammation, etc. The LOCs are able to closely replicate the dynamic conditions of the human brain and could be reliable platforms for drug screening applications. There are still many technical difficulties in establishing uniform and reproducible conditions, mainly due to the extreme complexity of the human brain. In this paper, we review the prospective of LOCs in the development of nanomedicines for brain angiogenesis–related conditions.

show abstract

“…Although IONPs present uncountable ways for cancer treatment and diagnosis, solid lipid particles should also be mentioned as powerful perspective tool in cancer therapy. Typically, photosensitizer such as phthalocyanine or temoporfin noncovalently bounded on the surface of solid lipid nanoparticles presents novel type of anticancer therapy, however, solid lipid nanoparticles are also appropriate for photothermal therapy using, for example, rapamycin loaded lipid‐polyaniline nanoparticle or simply they are perspective as targeted delivery system of anticancer drugs including paclitaxel, doxorubicin, or camptothecin . Even though solid lipid nanoparticles show excellent results in cancer therapy, IONPs enable more variable use as both therapeutic and diagnostic tool due to their unique magnetic and physico‐chemical properties and also as it will be described below their multifunctional application is investigated.…”

Section: Types Of Ionps Used In Cancer Treatment and Diagnosismentioning

confidence: 99%

Iron Oxide Nanoparticles: Innovative Tool in Cancer Diagnosis and Therapy

Martinková

Brtnický

Kynický

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Although cancer is one of the most dangerous and the second most lethal disease in the world, current therapy including surgery, chemotherapy, radiotherapy, etc., is highly insufficient not in the view of therapy success rate or the amount of side effects. Accordingly, procedures with better outcomes are highly desirable. Iron oxide nanoparticles (IONPs) present an innovative tool-ideal for innovation and implementation into practice. This review is focused on summarizing some well-known facts about pharmacokinetics, toxicity, and the types of IONPs, and furthermore, provides a survey of their use in cancer diagnosis and therapy.

show abstract

Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy

Cited by 75 publications

References 30 publications

Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer

Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer

Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases

Iron Oxide Nanoparticles: Innovative Tool in Cancer Diagnosis and Therapy

Contact Info

Product

Resources

About